NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive: CML patients with compound NAT2 590GG/ NAT2803AG, NAT2 590AG/ NAT2803AG, NAT2 590AG/ NAT2803GG, NAT2 590AA/ NAT2803AG and NAT2 590GG/ NAT2803AA genotypes were found to have a decreased risk.